Patient Leaflet Updated 09-Sep-2024 | Medice UK LTD
Vafseo (vadadustat) tablets (100214)
Vafseo 150 mg film-coated tablets
Vafseo 300 mg film-coated tablets
Vafseo 450 mg film-coated tablets
vadadustat
▼This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See the end of section 4 for how to report side effects.
1. What Vafseo is and what it is used for
2. What you need to know before you take Vafseo
3. How to take Vafseo
4. Possible side effects
5. How to store Vafseo
6. Contents of the pack and other information
Vafseo is a medicine that increases the amount of haemoglobin (the protein in your red blood cells that carries oxygen around the body) and the number of red blood cells in your blood. It contains the active substance vadadustat.
Vafseo is used to treat symptomatic anaemia (low levels of red blood cells or haemoglobin in your blood) that is associated with chronic kidney disease (CKD) in adults on chronic maintenance dialysis. When the amount of haemoglobin or the number of red blood cells is low, the cells in your body might not receive enough oxygen. Anaemia can cause symptoms such as tiredness, weakness, or shortness of breath.
Vafseo increases the level of a substance called “Hypoxia-Inducible Factor” (HIF), which increases the production of red blood cells when oxygen levels are low. By raising HIF levels, Vafseo increases the production of red blood cells and raises the levels of haemoglobin.
This improves the oxygen supply to your body and may reduce your anaemia symptoms.
Talk to your doctor, or pharmacist before taking Vafseo:
Blood tests
Chronic kidney disease can cause anaemia, which may increase the risk of heart and blood vessels problems and even death. Therefore, it is important to treat your anaemia. Your doctor will regularly check the amount of haemoglobin in your blood.
The treatment may increase liver enzymes. Your doctor will regularly check the amount of these enzymes in your blood at the start of your treatment, monthly for the first 3 months of your treatment and then as needed.
Do not give Vafseo to children and adolescents aged under 18 years. There is not enough information about its use in this age group.
Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines. Vafseo may affect the way other medicines work, and medicines may affect how Vafseo works.
In particular tell your doctor or pharmacist if you have taken, or are taking any of the following medicines:
Your doctor will decide how you should use these medicines during your treatment with Vafseo.
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
It is not known whether vadadustat passes into human milk.
Your doctor will decide whether you can take Vafseo during pregnancy or breast feeding.
It is not known if Vafseo has an effect on your fertility.
Vafseo is unlikely to affect your ability to drive and use machines.
This medicine contains less than 1 mmol sodium (23 mg) per film-coated tablet, that is to say essentially ‘sodium-free’.
Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.
Your doctor will tell you what dose of Vafseo to take.
Your doctor will check your haemoglobin levels regularly and increase or lower your Vafseo dose based on your haemoglobin levels.
Vafseo is taken by mouth as film-coated tablets.
Phosphate binders and Vafseo
If you are treated with phosphate binders which do not include iron (such as sevelamer carbonate or calcium acetate) or medicines containing calcium, magnesium or aluminium you should take Vafseo at least 1 hour before or 2 hours after taking those medicines, because otherwise vadadustat will not be properly absorbed by your body. If the phosphate binder you are taking contains iron, see the information below.
Iron containing products and Vafseo
If you take medicines containing iron or phosphate binders containing iron you should take Vafseo at least 1 hour before those products. Vadadustat will not be properly absorbed by your body if you do not follow these instructions.
Your doctor will tell you what dose of Vafseo to take. Treatment with Vafseo will start at a daily dose of 300 mg. Thereafter, your doctor may either increase or decrease your daily dose in steps of 150 mg. The lowest dose is 150 mg per day and the highest dose is 600 mg per day.
Always take Vafseo as prescribed by your doctor.
It is important that your doctor regularly checks the amount of haemoglobin in your blood. Based on these test results your doctor may increase or lower your dose. If the amount of haemoglobin in your blood becomes too high your treatment will be stopped. Do not restart your treatment until your doctor tells you to do so and use only the dose your doctor prescribes.
Your doctor will monitor your liver enzyme levels (ALT, AST, and bilirubin) before your treatment starts, and monthly thereafter for at least 3 months.
If you take more tablets or a higher dose than you should, contact your doctor straight away.
If you stop taking Vafseo, your anaemia may get worse. Do not stop taking this medicine unless your doctor tells you to do so.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Contact your doctor straight away if you get any of the following:
Very common (may affect more than 1 in 10 people)
Talk to your doctor if you get any of the following side effects:
Very common (may affect more than 1 in 10 people)
Common (may affect up to 1 in 10 people):
Uncommon (may affect up to 1 in 100 people):
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton and blister after EXP. The expiry date refers to the last day of that month.
This medicine does not require any special storage conditions.
Do not throw away any medicines via wastewater, or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
The active substance is vadadustat.
Vafseo 150 mg film-coated tablets:
Vafseo 300 mg film-coated tablets:
Vafseo 450 mg film-coated tablets
The other ingredients are:
Tablet core
Microcrystalline cellulose, sodium starch glycolate, hypromellose, colloidal silicon dioxide, magnesium stearate.
Tablet coating:
Polyvinyl alcohol (E1203), macrogol (E 1521)/polyethylene glycol (PEG), talc.
Vafseo 150 mg film-coated tablets
Titanium dioxide
Vafseo 300 mg film-coated tablets
Titanium dioxide, yellow iron oxide
Vafseo 450 mg film-coated tablets
Titanium dioxide, iron oxide red and ferrosoferric oxide
Vafseo 150 mg film-coated tablets are round and white, debossed with “VDT” on one side and “150” on the other side.
Vafseo 300 mg film-coated tablets are oval and yellow, debossed with “VDT” on one side and “300” on the other side.
Vafseo 450 mg film-coated tablets are oval and pink, debossed with “VDT” on one side and “450” on the other side.
Vafseo film-coated tablets are supplied in cartons containing 28 or 98 film-coated tablets in PVC/aluminium foil blisters.
For any information about this medicine, please contact:
This leaflet was last revised in 04/2024
The Rotunda, 1 Old London Road, Hertford, Hertfordshire, SG13 7LA, UK
0204 582 2845
0204 582 2845